Intensified Antituberculosis Therapy Regimen Containing Higher Dose Rifampin for Tuberculous Meningitis: A Systematic Review and Meta-Analysis.
high-dose rifampin
meta-analysis
pharmacokinetics parameters
survival
tuberculous meningitis
Journal
Frontiers in medicine
ISSN: 2296-858X
Titre abrégé: Front Med (Lausanne)
Pays: Switzerland
ID NLM: 101648047
Informations de publication
Date de publication:
2022
2022
Historique:
received:
25
11
2021
accepted:
19
01
2022
entrez:
14
3
2022
pubmed:
15
3
2022
medline:
15
3
2022
Statut:
epublish
Résumé
Tuberculous meningitis is difficult to diagnose and is associated with high mortality. Recently, several studies evaluated the intensified regimen containing higher dose rifampin to treat tuberculous meningitis. However, this topic remains to be concluded. Therefore, this systematic review and meta-analysis was conducted to evaluate pharmacokinetics parameters, safety, and survival benefits of high-dose rifampin for tuberculous meningitis. Data were searched from PubMed, EMBASE, The Cochrane Library, and Web of Science for studies describing an antituberculosis regimen including a higher dose of rifampin for patients with tuberculous meningitis. The quality of eligible studies was evaluated There were six randomized control trails included in this meta-analysis. The results showed that the concentration in plasma and cerebrospinal fluid (CSF) were significantly higher in the intervention group than the standard group [MD = 22.08, 95%CI (16.24, 27.92), This meta-analysis suggested that the intensified treatment regimen including a higher dose of rifampin significantly increased the rifampin concentration both in the plasma and CSF, and it was safe in patients with tuberculous meningitis, but resulted in no improvement in survival rates.
Sections du résumé
Background
UNASSIGNED
Tuberculous meningitis is difficult to diagnose and is associated with high mortality. Recently, several studies evaluated the intensified regimen containing higher dose rifampin to treat tuberculous meningitis. However, this topic remains to be concluded. Therefore, this systematic review and meta-analysis was conducted to evaluate pharmacokinetics parameters, safety, and survival benefits of high-dose rifampin for tuberculous meningitis.
Method
UNASSIGNED
Data were searched from PubMed, EMBASE, The Cochrane Library, and Web of Science for studies describing an antituberculosis regimen including a higher dose of rifampin for patients with tuberculous meningitis. The quality of eligible studies was evaluated
Results
UNASSIGNED
There were six randomized control trails included in this meta-analysis. The results showed that the concentration in plasma and cerebrospinal fluid (CSF) were significantly higher in the intervention group than the standard group [MD = 22.08, 95%CI (16.24, 27.92),
Conclusion
UNASSIGNED
This meta-analysis suggested that the intensified treatment regimen including a higher dose of rifampin significantly increased the rifampin concentration both in the plasma and CSF, and it was safe in patients with tuberculous meningitis, but resulted in no improvement in survival rates.
Identifiants
pubmed: 35280900
doi: 10.3389/fmed.2022.822201
pmc: PMC8916538
doi:
Types de publication
Systematic Review
Langues
eng
Pagination
822201Informations de copyright
Copyright © 2022 Zhang, Wang and He.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Klin Wochenschr. 1985 Dec 2;63(23):1205-11
pubmed: 4087830
J Infect Dis. 2018 Aug 14;218(6):991-999
pubmed: 29718390
Int J Tuberc Lung Dis. 2020 May 1;24(5):499-505
pubmed: 32398199
Clin Pharmacokinet. 2003;42(9):819-50
pubmed: 12882588
Clin Pharmacol Ther. 2018 Apr;103(4):674-683
pubmed: 28653479
Clin Infect Dis. 2021 Sep 7;73(5):876-884
pubmed: 33693537
Am J Respir Crit Care Med. 2018 Sep 1;198(5):657-666
pubmed: 29954183
Int J Tuberc Lung Dis. 2000 Sep;4(9):796-806
pubmed: 10985648
N Engl J Med. 2016 Jan 14;374(2):124-34
pubmed: 26760084
Clin Infect Dis. 2017 May 15;64(10):1350-1359
pubmed: 28205671
Lancet Infect Dis. 2013 Jan;13(1):27-35
pubmed: 23103177
Clin Pharmacol Ther. 2020 Apr;107(4):1023-1033
pubmed: 31956998
Clin Infect Dis. 2021 Nov 2;73(9):e3374-e3376
pubmed: 32857152
Clin Infect Dis. 2018 Aug 16;67(5):708-716
pubmed: 29514175
Paediatr Drugs. 2013 Apr;15(2):93-117
pubmed: 23529866
Semin Neurol. 2018 Apr;38(2):226-237
pubmed: 29791949
Int J Tuberc Lung Dis. 2016 Jun;20(6):819-26
pubmed: 27155187
Wellcome Open Res. 2019 Nov 5;4:167
pubmed: 32118118
Clin Pharmacokinet. 2019 Sep;58(9):1103-1129
pubmed: 31049868
Antimicrob Agents Chemother. 2018 Nov 26;62(12):
pubmed: 30224533
Int J Tuberc Lung Dis. 2016 Jun;20(6):832-8
pubmed: 27155189
Antimicrob Agents Chemother. 2017 Oct 24;61(11):
pubmed: 28827417
Respirology. 2006 Nov;11(6):699-707
pubmed: 17052297
Clin Pharmacokinet. 1978 Mar-Apr;3(2):108-27
pubmed: 346286
J Antimicrob Chemother. 2001 Jul;48 Suppl 1:5-16
pubmed: 11420333
Antimicrob Agents Chemother. 2007 Nov;51(11):3781-8
pubmed: 17724157
Antimicrob Agents Chemother. 2007 Jul;51(7):2546-51
pubmed: 17452486
Int J Infect Dis. 2019 Jul;84:15-21
pubmed: 31051278
Tuberculosis (Edinb). 2011 May;91(3):196-207
pubmed: 21429802
Nat Rev Neurol. 2017 Oct;13(10):581-598
pubmed: 28884751
J Infect Dis. 2013 Nov 1;208(9):1464-73
pubmed: 23901086
Tuberculosis (Edinb). 2010 Sep;90(5):279-92
pubmed: 20709598
Am J Respir Crit Care Med. 2015 May 1;191(9):1058-65
pubmed: 25654354
Clin Infect Dis. 2020 Nov 5;71(8):1817-1823
pubmed: 31665299
Int J Tuberc Lung Dis. 2013 Feb;17(2):221-4
pubmed: 23317957
Antimicrob Agents Chemother. 2021 Jul 16;65(8):e0014021
pubmed: 33972248
Arch Dis Child. 2022 Jan;107(1):70-77
pubmed: 34183327
Spine (Phila Pa 1976). 2015 Nov;40(21):1660-73
pubmed: 26208232